Marie E. Faughnan

MD, MSc

Scientist

Biography

Dr. Marie E. Faughnan is a Respirologist and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital. She is an Associate Professor at the University of Toronto. Dr. Faughnan is a clinical epidemiologist, with a research focus on clinical and mechanistic aspects of vascular malformations, with a specific expertise in hereditary hemorrhagic telangiectasia (HHT). Dr. Faughnan is the Director of the Toronto Hereditary Hemorrhagic Telangiectasia Centre and the Scientific Director for CureHHT. Dr. Faughnan has also led the development and publication of the first International HHT Guidelines.

Recent Publications

  1. Thompson, KP, Nelson, J, Kim, H, Pawlikowska, L, Marchuk, DA, Lawton, MT et al.. Predictors of mortality in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2021;16 (1):12. doi: 10.1186/s13023-020-01579-2. PubMed PMID:33407668 PubMed Central PMC7789194.
  2. Kilian, A, Clancy, MS, Olitsky, S, Gossage, JR, Faughnan, ME. Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): A survey of HHT Centers of Excellence. Vasc Med. 2021;26 (1):53-55. doi: 10.1177/1358863X20974452. PubMed PMID:33375920 PubMed Central PMC7879226.
  3. Han, Z, Shaligram, S, Faughnan, ME, Clark, D, Sun, Z, Su, H et al.. Reduction of endoglin receptor impairs mononuclear cell-migration. Explor Med. 2020;1 :136-148. doi: 10.37349/emed.2020.00010. PubMed PMID:32954380 PubMed Central PMC7500529.
  4. Faughnan, ME, Mager, JJ, Hetts, SW, Palda, VA, Lang-Robertson, K, Buscarini, E et al.. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med. 2020;173 (12):989-1001. doi: 10.7326/M20-1443. PubMed PMID:32894695 .
  5. Kilian, A, Latino, GA, White, AJ, Clark, D, Chakinala, MM, Ratjen, F et al.. Genotype-Phenotype Correlations in Children with HHT. J Clin Med. 2020;9 (9):. doi: 10.3390/jcm9092714. PubMed PMID:32842615 PubMed Central PMC7565052.
  6. Stewart, RJ, Faughnan, ME. Living donor liver transplant between physicians: two viewpoints. CMAJ. 2020;192 (26):E729-E731. doi: 10.1503/cmaj.200231. PubMed PMID:32601255 PubMed Central PMC7828883.
  7. Wu, V, Kell, E, Faughnan, ME, Lee, JM. In-Office KTP Laser for Treating Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis. Laryngoscope. 2021;131 (3):E689-E693. doi: 10.1002/lary.28824. PubMed PMID:32557619 .
  8. Kennedy, SA, Faughnan, ME, Vozoris, NT, Prabhudesai, V. Reperfusion of Pulmonary Arteriovenous Malformations Following Embolotherapy: A Randomized Controlled Trial of Detachable Versus Pushable Coils. Cardiovasc Intervent Radiol. 2020;43 (6):904-909. doi: 10.1007/s00270-020-02422-8. PubMed PMID:32020296 .
  9. Snellings, DA, Gallione, CJ, Clark, DS, Vozoris, NT, Faughnan, ME, Marchuk, DA et al.. Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1. Am J Hum Genet. 2019;105 (5):894-906. doi: 10.1016/j.ajhg.2019.09.010. PubMed PMID:31630786 PubMed Central PMC6848992.
  10. Lee, JM, Wu, V, Faughnan, ME, Lasso, A, Figol, A, Kilty, SJ et al.. Prospective pilot study of Floseal® for the treatment of anterior epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT). J Otolaryngol Head Neck Surg. 2019;48 (1):48. doi: 10.1186/s40463-019-0379-y. PubMed PMID:31615556 PubMed Central PMC6794791.
Search PubMed

Affiliations & Other Activities

  • Director, Pulmonary Function Laboratory, St. Michael’s Hospital
  • Director, Toronto Hereditary Hemorrhagic Telangiectasia, The Hospital for Sick Children
X